AU6819494A - Transgenic non-human animals capable of producing heterologous antibodies - Google Patents

Transgenic non-human animals capable of producing heterologous antibodies

Info

Publication number
AU6819494A
AU6819494A AU68194/94A AU6819494A AU6819494A AU 6819494 A AU6819494 A AU 6819494A AU 68194/94 A AU68194/94 A AU 68194/94A AU 6819494 A AU6819494 A AU 6819494A AU 6819494 A AU6819494 A AU 6819494A
Authority
AU
Australia
Prior art keywords
human animals
transgenic non
heterologous antibodies
producing heterologous
animals capable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68194/94A
Inventor
Robert M. Kay
Nils Lonberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GenPharm International Inc
Original Assignee
GenPharm International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US053131 priority Critical
Priority to US08/053,131 priority patent/US5661016A/en
Priority to US096762 priority
Priority to US08/096,762 priority patent/US5814318A/en
Priority to US155301 priority
Priority to US15530193A priority
Priority to US16173993A priority
Priority to US16569993A priority
Priority to US165699 priority
Priority to US161739 priority
Priority to US209741 priority
Priority to US20974194A priority
Application filed by GenPharm International Inc filed Critical GenPharm International Inc
Priority to PCT/US1994/004580 priority patent/WO1994025585A1/en
Publication of AU6819494A publication Critical patent/AU6819494A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Humanized animals, e.g. knockin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/30Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
AU68194/94A 1990-08-29 1994-04-25 Transgenic non-human animals capable of producing heterologous antibodies Abandoned AU6819494A (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US053131 1993-04-26
US08/053,131 US5661016A (en) 1990-08-29 1993-04-26 Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US096762 1993-07-22
US08/096,762 US5814318A (en) 1990-08-29 1993-07-22 Transgenic non-human animals for producing heterologous antibodies
US15530193A true 1993-11-18 1993-11-18
US155301 1993-11-18
US16173993A true 1993-12-03 1993-12-03
US16569993A true 1993-12-10 1993-12-10
US165699 1993-12-10
US161739 1993-12-10
US20974194A true 1994-03-09 1994-03-09
US209741 1994-03-09
PCT/US1994/004580 WO1994025585A1 (en) 1993-04-26 1994-04-25 Transgenic non-human animals capable of producing heterologous antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU39078/95A Division AU3907895A (en) 1990-08-29 1995-11-24 Transgenic non-human animals capable of producing heterologous antibodies

Publications (1)

Publication Number Publication Date
AU6819494A true AU6819494A (en) 1994-11-21

Family

ID=27556670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68194/94A Abandoned AU6819494A (en) 1990-08-29 1994-04-25 Transgenic non-human animals capable of producing heterologous antibodies

Country Status (5)

Country Link
EP (1) EP0754225A4 (en)
JP (3) JPH08509612A (en)
AU (1) AU6819494A (en)
CA (1) CA2161351C (en)
WO (1) WO1994025585A1 (en)

Families Citing this family (567)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69637481D1 (en) * 1995-04-27 2008-05-15 Amgen Fremont Inc Human antibodies to IL-8 derived from immunized Xenomae
AU2008202860B9 (en) * 1995-04-27 2012-03-29 Amgen Fremont Inc. Human Antibodies Derived From Immunized Xenomice
AU4376400A (en) * 1995-04-27 2000-11-30 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69633238D1 (en) 1995-06-07 2004-09-30 Jacob N Wohlstadter Method for increasing enzyme diversity
US5914256A (en) * 1995-06-07 1999-06-22 Wohlstadter Jacob N Method for promoting enzyme diversity
US5919681A (en) * 1995-06-07 1999-07-06 Wohlstadter Jacob N Method for promoting enzyme diversity
JPH11510047A (en) * 1995-07-21 1999-09-07 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ Compositions and methods for catalyzing the hydrolysis of HIV gp120
AU2405297A (en) 1996-04-23 1997-11-12 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
NZ331978A (en) * 1996-05-04 2000-05-26 Zeneca Ltd Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
AU2008200005B2 (en) * 1996-12-03 2012-05-17 Amgen Fremont Inc. Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom
PT942968E (en) 1996-12-03 2008-03-27 Amgen Fremont Inc Fully human antibodies that bind egfr
US6080910A (en) * 1997-02-20 2000-06-27 Case Western Reserve University Transgenic knockout animals lacking IgG3
ES2382488T3 (en) 1997-03-21 2012-06-08 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for diseases mediated by sensitized t cells comprising an il-6 antagonist as an active ingredient
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9711167D0 (en) * 1997-05-31 1997-07-23 Babraham The Inst Telomere-associated chromosome fragmentation
DE69839517D1 (en) 1997-08-15 2008-07-03 Chugai Pharmaceutical Co Ltd Preventiva or arzneia containing neutralizing anti-il6 receptor antibodies for reducing urinary proteins in systemic lupus erythematosus
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
EP1136548A4 (en) 1998-11-04 2002-09-25 Chugai Pharmaceutical Co Ltd Novel trypsin family serine proteases
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Anti-CTLA-4 human monoclonal antibodies
EE05483B1 (en) 1998-12-23 2011-10-17 Pfizer, Inc. Anti-CTLA-4 human monoclonal antibodies
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP4590107B2 (en) 1999-04-09 2010-12-01 中外製薬株式会社 New fetal gene
ES2339843T3 (en) 1999-06-02 2010-05-26 Chugai Seiyaku Kabushiki Kaisha Protein receiving hematopoyetina novedosa, nr10.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
ES2307526T3 (en) 1999-08-23 2008-12-01 Chugai Seiyaku Kabushiki Kaisha Potentials of the expression of the antigen hm1.24.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
AU6871900A (en) 1999-09-06 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Tsg-like gene
WO2001019394A2 (en) * 1999-09-15 2001-03-22 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
DE60042220D1 (en) 1999-09-21 2009-06-25 Chugai Pharmaceutical Co Ltd Use of transportation oatp-c to screening test substances
EP2351483A1 (en) 1999-10-01 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of blood coagulation-related diseases
KR100833367B1 (en) 2000-01-24 2008-05-28 하루오 스기야마 Wt1-interacting protein wtip
JP4846169B2 (en) 2000-04-28 2011-12-28 中外製薬株式会社 Cell growth inhibitor
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
JP3597140B2 (en) 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
NZ562811A (en) 2000-08-07 2009-05-31 Centocor Inc Anti-TNF antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1399483B1 (en) 2001-01-05 2010-04-14 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
EP1364657B1 (en) 2001-02-07 2016-12-28 Chugai Seiyaku Kabushiki Kaisha Remedies for myelocytic leukemia
EP1370588A2 (en) 2001-02-12 2003-12-17 Medarex, Inc. Human monoclonal antibodies to fc alpha receptor (cd89)
MXPA03008955A (en) 2001-04-02 2004-02-18 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases.
BR0214168A (en) 2001-11-14 2004-09-14 Centocor Inc Anti-il-6 antibodies, compositions, methods and uses
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
US20050171339A1 (en) 2001-12-28 2005-08-04 Izumi Sugo Method of stabilizing protein
CN1638800B (en) 2002-01-09 2014-07-16 梅达雷克斯有限责任公司 Human monoclonal antibodies against CD30
RU2335299C2 (en) 2002-02-14 2008-10-10 Чугаи Сейяку Кабусики Кайся Preparations in the form of solutions, containing antibodies
DK1485477T3 (en) 2002-02-25 2009-08-10 Genentech Inc New type 1 cytokine receptor GLM-R
US7666610B2 (en) 2002-03-29 2010-02-23 Chugai Seiyaku Kabushiki Kaisha Expressing transporters on viral envelopes
IL164287D0 (en) 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
NZ554740A (en) 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
CN101613405A (en) 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 Gene relevant and polypeptide with human colon carcinoma
DE60336227D1 (en) 2002-06-06 2011-04-14 Oncotherapy Science Inc Genes and proteins related to human colonic cancer
JP4489591B2 (en) 2002-08-27 2010-06-23 中外製薬株式会社 Method for stabilizing protein solution formulations
AU2002338020A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
EP1561756B1 (en) 2002-09-11 2015-12-23 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
TW200413539A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
KR100932340B1 (en) 2002-10-17 2009-12-16 젠맵 에이/에스 Human monoclonal antibodies against CD20
CN1891826B (en) 2002-10-22 2011-09-14 卫材R&D管理有限公司 Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
US7632935B2 (en) 2002-10-30 2009-12-15 Chungai Seiyaku Kabushiki Kaisha DNA encoding a mast cell-derived membrane protein
WO2004045512A2 (en) 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
JP4754219B2 (en) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド Antibodies directed against tumor necrosis factor and their use
AT527278T (en) 2002-12-16 2011-10-15 Genmab As Human monoclonal antibody to interleukin 8 (il-8)
JP2007525434A (en) 2003-03-19 2007-09-06 アブジェニックス インコーポレイテッド Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof.
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2004106515A1 (en) 2003-05-28 2004-12-09 Scimedia Ltd. Anti-bambi antibody and diagnostic or remedy for colon cancer and liver cancer containing the same
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1635763B1 (en) 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
EP1642971B1 (en) 2003-06-18 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
BRPI0411803A (en) 2003-06-27 2006-05-23 Abgenix Inc antibodies directed to epidermal growth factor receptor deletion mutants and their uses
EP1791868B1 (en) 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
WO2005047459A2 (en) 2003-08-04 2005-05-26 University Of Massachusetts Sars nucleic acids, proteins, antibodies, and uses thereof
CA2535156A1 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
EP1652923B1 (en) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP1693448A4 (en) 2003-10-14 2008-03-05 Chugai Pharmaceutical Co Ltd Double specific antibodies substituting for functional protein
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
WO2005054467A1 (en) 2003-12-03 2005-06-16 Chugai Seiyaku Kabushiki Kaisha EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN β-ACTIN PROMOTER
ES2537163T3 (en) 2003-12-10 2015-06-03 E. R. Squibb & Sons, L.L.C. IP-10 antibodies and their uses
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
US20080206229A1 (en) 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
ES2643760T3 (en) 2004-02-06 2017-11-24 University Of Massachusetts Antibodies against Clostridium difficile toxins and their uses
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
JP2008507257A (en) 2004-03-19 2008-03-13 アムゲン・インコーポレーテッド Reduced risk of human anti-human antibodies through manipulation of V genes
AT496142T (en) 2004-03-23 2011-02-15 Oncotherapy Science Inc Method for the diagnosis of non-small cellulose cancer
ES2403055T3 (en) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anti-P-selectin antibodies
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
KR20120133403A (en) 2004-06-01 2012-12-10 도만티스 리미티드 Bispecific fusion antibodies with enhanced serum half-life
ES2643237T3 (en) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Interferon alfa 1 receptor antibodies and their uses
RU2427588C2 (en) 2004-07-09 2011-08-27 Чугаи Сейяку Кабусики Кайся Glypican-3 antibody
US20080199437A1 (en) 2004-07-22 2008-08-21 Eisai Co., Ltd. Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
JP2008514730A (en) 2004-10-01 2008-05-08 メダレックス, インク.Medarex, Inc. Method of treating CD30 positive lymphoma
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
US20060130157A1 (en) 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
DE602005025525D1 (en) 2004-11-17 2011-02-03 Amgen Inc Complete human monoclonal antibodies against il-13
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
EP1838737B1 (en) 2004-12-20 2011-04-06 Amgen Fremont Inc. Binding proteins specific for human matriptase
RU2394839C2 (en) 2004-12-21 2010-07-20 Астразенека Аб Antibodies against angiopoietin-2 and use thereof
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
JP5109131B2 (en) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 Method for diagnosing bladder cancer
US8207303B2 (en) 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
TWI406870B (en) 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
US20090130662A1 (en) 2005-03-14 2009-05-21 Link Genomics, Inc Method for Diagnosis of Prostate Cancer
AU2006226733C9 (en) 2005-03-23 2019-03-14 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2006109592A1 (en) 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
CN103059138B (en) 2005-05-09 2015-10-28 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and use anti-PD-1 antibody to carry out the method for Therapeutic cancer
CN101237890A (en) 2005-06-10 2008-08-06 中外制药株式会社 Stabilizer for protein preparation comprising meglumine and use thereof
DK1896073T3 (en) 2005-06-30 2013-06-03 Janssen Biotech Inc Anti-il antibodies, compositions, procedures and applications
CN105330741A (en) 2005-07-01 2016-02-17 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
DE602006020451D1 (en) 2005-07-27 2011-04-14 Oncotherapy Science Inc Genes and polypeptides related to prostate cancer
JP5230420B2 (en) 2005-08-18 2013-07-10 ゲンマブ エー/エス Treatment with CD4 binding peptides and radiation
ES2527961T3 (en) 2005-09-26 2015-02-02 Medarex, L.L.C. human monoclonal antibodies to CD70
DK1939288T3 (en) 2005-09-29 2013-03-11 Eisai R&D Man Co Ltd T cell adhesion molecule and antibody directed against the molecule
BRPI0617378A2 (en) 2005-10-14 2011-07-26 Univ Fukuoka agent for suppressing damage to a transplanted islet after islet transplantation and uses of an il-6 inhibitor
KR20080049113A (en) 2005-10-21 2008-06-03 노파르티스 아게 Human antibodies against il-13 and therapeutic uses
WO2007046489A1 (en) 2005-10-21 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for heart disease
JPWO2007049770A1 (en) 2005-10-28 2009-04-30 明治製菓株式会社 Pseudomonas aeruginosa outer membrane protein PA5158
WO2007059082A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization Agents to suppress the induction of cytotoxic T lymphocytes
JPWO2007061029A1 (en) 2005-11-25 2009-05-07 学校法人慶應義塾 Prostate cancer treatment
JP2009518446A (en) 2005-12-07 2009-05-07 メダレックス インコーポレーティッド CTLA-4 antibody dose escalation regimen
WO2007067992A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
AU2006326649B2 (en) 2005-12-13 2011-03-24 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
WO2007077934A1 (en) 2005-12-28 2007-07-12 Asubio Pharma Co., Ltd. Anti-periostin antibody and pharmaceutical composition for preventing or treating periostin-related disease containing the same
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antibody-containing stabilizing preparation
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag Antibodies directed to HER-3 receptor (the human epidermal growth factor-3) and their uses
EP1984403A2 (en) 2006-01-12 2008-10-29 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
ES2396569T3 (en) 2006-01-17 2013-02-22 Medarex, Inc. Monoclonal antibodies against CD30 that lack fucosyl and xylosyl moieties
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
US8084044B2 (en) 2006-03-30 2011-12-27 Meiji Seika Kaisha, Ltd. Pseudomonas aeruginosa outer membrane protein PA0427
CA2638774C (en) 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US8071323B2 (en) 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
WO2007116962A1 (en) 2006-04-07 2007-10-18 Osaka University Muscle regeneration promoter
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2011513B1 (en) 2006-04-25 2016-10-19 The University of Tokyo Therapeutic agents for alzheimer's disease and cancer
EP2047863B1 (en) 2006-06-08 2013-07-31 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
JPWO2007145227A1 (en) 2006-06-14 2009-11-05 中外製薬株式会社 Hematopoietic stem cell increase promoter
AU2007273507A1 (en) 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2574625B1 (en) 2006-07-21 2015-02-25 HuBit genomix, Inc. Remedy for renal disease
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab Specific binding agent for the receptor platelet-derived growth factor (PDGFR-alpha); nucleic acid molecule encoding it; vector and host cell comprising it; conjugate comprising the agent; and use of the agent of a
CN103524619B (en) 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 Antibody and application thereof for α V β 6
CA2658050A1 (en) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-desmoglein 3 antibodies
US20110182904A1 (en) 2006-09-05 2011-07-28 Deborah Zimmerman Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
SI2081595T1 (en) 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US8007797B2 (en) 2006-09-28 2011-08-30 Merck Serono S.A. Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use
ME02269B (en) 2006-10-02 2016-04-28 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
CA2665528C (en) 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
EP2068922B1 (en) 2006-10-19 2012-06-27 CSL Limited Anti-il-13r alpha 1 antibodies and their uses thereof
US9023993B2 (en) 2006-10-20 2015-05-05 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
US20100061933A1 (en) 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
CL2007003291A1 (en) 2006-11-15 2008-07-04 Medarex Inc isolated human monoclonal antibody that links BTLA protein or fragments therefrom; nucleic acid encoding it; Method of production; and immunoconjugate composition that comprises; and method for inhibiting the growth of tumor cells and
CN101626785A (en) 2006-11-17 2010-01-13 财团法人阪大微生物病研究会 Nerve elongation promoter and elongation inhibitor
CA2671457C (en) 2006-12-01 2017-09-26 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human monoclonal antibody anti-CD19; composition comprising; and method of inhibiting the growth of tumor cells.
AU2007333098A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
US20100111852A1 (en) 2006-12-14 2010-05-06 Forerunner Pharma Research Co., Ltd. Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
EP2123676A4 (en) 2007-01-05 2011-01-05 Univ Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
AU2008208321B2 (en) 2007-01-23 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Chronic rejection inhibitor
WO2008096817A1 (en) 2007-02-09 2008-08-14 Eisai R & D Management Co., Ltd. Gaba neuron progenitor cell marker 65b13
EP2123299A4 (en) 2007-02-15 2011-10-05 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
JP5564266B2 (en) 2007-02-16 2014-07-30 メリマック ファーマシューティカルズ インコーポレーティッド Antibodies against ERBB3 and uses thereof
CN101679512A (en) 2007-02-21 2010-03-24 马萨诸塞州大学 Anti-hepatitis c virus (HCV) people antibody and uses thereof
CA2679266A1 (en) 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
CL2008000719A1 (en) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Therapeutic agent for cancer resistant to chemotherapeutic agents comprising an antibody that recognizes HLA class I as an active ingredient; pharmaceutical composition comprising said antibody; and method of treating cancer resistant
CN101679521B (en) 2007-03-22 2014-03-12 拜奥根Idec马萨诸塞公司 Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
ES2667863T3 (en) 2007-03-29 2018-05-14 Genmab A/S Bispecific antibodies and their production methods
FI20075278A0 (en) 2007-04-20 2007-04-20 Biotie Therapies Corp Novel completely human anti-VAP-1 monoclonal antibodies
JP5117765B2 (en) 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
AU2008255350B2 (en) 2007-05-31 2014-07-10 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
BRPI0812400A2 (en) 2007-06-05 2014-10-29 Univ Yale Unit, hybridoma, pharmaceutical composition, method for identifying a unit, antibody isolated to a same antigen connection unit, peptides molecule, and unit use.
WO2009001840A1 (en) 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. Anti-prominin-1 antibody having adcc activity or cdc activity
WO2009001940A1 (en) 2007-06-27 2008-12-31 Asubio Pharma Co., Ltd. Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
WO2009008414A1 (en) 2007-07-10 2009-01-15 Shionogi & Co., Ltd. Monoclonal antibody having neutralizing activity against mmp13
WO2009014263A1 (en) 2007-07-26 2009-01-29 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
AU2008317495B2 (en) 2007-08-02 2013-08-01 Novimmune S.A. Anti-RANTES antibodies and methods of use thereof
JP5588866B2 (en) 2007-08-10 2014-09-10 メダレックス エル.エル.シー. HCO 32 and HCO 27 and related examples
JP5493076B2 (en) 2007-08-20 2014-05-14 オンコセラピー・サイエンス株式会社 CDCA1 peptide and drug containing the same
CN104774261B (en) 2007-08-20 2018-03-06 肿瘤疗法科学股份有限公司 FOXM1 peptides and the medicament for including FOXM1 peptides
US8455444B2 (en) 2007-08-20 2013-06-04 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
PE20140221A1 (en) 2007-08-23 2014-02-21 Amgen Inc Antigen binding proteins against converstasa proprotein subtilisin / kexin type 9 (PCSK9)
EP2190469B1 (en) 2007-09-04 2015-02-25 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
BRPI0817255A2 (en) 2007-09-26 2017-06-06 Amgen Inc heparin-binding epidermal growth factor-like growth factor antigen-binding proteins.
CL2009000647A1 (en) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent to attenuate a side effect comprising said antibody; method for treating or preventing liver cancer in a subject.
MX2010003139A (en) 2007-10-02 2010-04-07 Chugai Pharmaceutical Co Ltd Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient.
TWI489993B (en) 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
CA2701338C (en) 2007-10-15 2018-09-18 Chugai Seiyaku Kabushiki Kaisha Method for production of antibody
KR20100115340A (en) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Antibody capable of specifically binding to aβ oligomer, and use thereof
PL2567709T3 (en) 2007-11-02 2018-06-29 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
SG187482A1 (en) 2007-11-07 2013-02-28 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
KR20100097684A (en) 2007-11-12 2010-09-03 우드라이 파마 게엠베하 Axl antibodies
AU2008321840B2 (en) 2007-11-14 2014-02-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-GPR49 antibody
EP2228392A4 (en) 2007-11-15 2012-05-02 Chugai Pharmaceutical Co Ltd Monoclonal antibody capable of binding to anexelekto, and use thereof
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
CN101939424B (en) 2007-12-05 2016-12-28 中外制药株式会社 Anti-NR10 antibody and application thereof
JPWO2009075344A1 (en) 2007-12-12 2011-04-28 独立行政法人国立がん研究センター MLL leukemia and MOZ leukemia therapeutic agent using M-CSF receptor as molecular target, and use thereof
CN110698561A (en) 2007-12-14 2020-01-17 诺沃—诺迪斯克有限公司 Anti-human NKG2D antibodies and uses thereof
EP2236515A4 (en) 2007-12-25 2012-10-31 Meiji Seika Kaisha Component protein pa1698 for type-iii secretion system of pseudomonas aeruginosa
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Liquid formulation containing a high concentration of antibody
WO2009088032A1 (en) 2008-01-10 2009-07-16 Shionogi & Co., Ltd. Antibody directed against pcrv
RU2010133547A (en) 2008-01-11 2012-02-20 Дзе Юниверсити Оф Токио (Jp) Anti-cldn antibodies
NZ600205A (en) 2008-01-25 2013-12-20 Univ Aarhus Selective exosite inhibition of papp-a activity against igfbp-4
BRPI0906387A2 (en) 2008-02-05 2015-07-07 Squibb Bristol Myers Co Alpha 5 - beta 1 antibodies and their uses
EP2246427B1 (en) 2008-02-08 2016-11-30 Immunas Pharma, Inc. Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof
CA2717569A1 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
WO2009119794A1 (en) 2008-03-27 2009-10-01 タカラバイオ株式会社 Prophylactic/therapeutic agent for infectious disease
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
KR101665729B1 (en) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 Neuroinvasion inhibitor
WO2009154025A1 (en) 2008-06-20 2009-12-23 国立大学法人岡山大学 ANTIBODY AGAINST OXIDIZED LDL/β2GPI COMPLEX AND USE OF THE SAME
EP2328616B1 (en) 2008-08-05 2015-04-29 Novartis AG Compositions and methods for antibodies against complement protein c5
EP2324852B1 (en) 2008-08-07 2015-07-08 Nagasaki University Therapeutic or prophylactic agent for generalized pain syndrome
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc human antibodies that bind to the gene 3 of lymphocyte activation (LAG-3) and uses these
EP2326668B1 (en) 2008-08-14 2018-01-17 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/il-23 antibodies
CN102264763B (en) 2008-09-19 2016-04-27 米迪缪尼有限公司 Antibody being oriented to DLL4 and uses thereof
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
KR20190065477A (en) 2008-09-30 2019-06-11 아블렉시스, 엘엘씨 Non-human mammals for the production of chimeric antibodies
WO2010051288A1 (en) 2008-10-27 2010-05-06 Revivicor, Inc. Immunocompromised ungulates
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP3153524A1 (en) 2008-12-03 2017-04-12 Genmab A/S Antibody variants having modifications in the constant region
JP2010210772A (en) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
CN102300874B (en) 2008-12-08 2015-08-05 卡姆普根有限公司 TMEM154 polypeptide and polynucleotide and as the purposes of drug targets producing medicine and biological products
ES2604635T3 (en) 2008-12-09 2017-03-08 Genmab A/S Human antibodies against human tissue factor
US8877449B2 (en) 2008-12-22 2014-11-04 Eisai R&D Management Co., Ltd. Method for obtaining pancreatic progenitor cell using NEPH3
JP5756292B2 (en) 2008-12-22 2015-07-29 中外製薬株式会社 Anti-HS6ST2 antibody and use thereof
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
JP6009733B2 (en) 2008-12-25 2016-10-19 国立大学法人 東京大学 Diagnosis and treatment of cancer using anti-tm4sf20 antibody
MX2011006908A (en) 2008-12-26 2011-10-06 Univ Tokio Diagnosis and treatment of cancer using anti-lgr7 antibody.
PT2403878T (en) 2009-03-05 2017-09-01 Squibb & Sons Llc Fully human antibodies specific to cadm1
EP2412825B8 (en) 2009-03-24 2018-01-10 Riken Leukemia stem cell markers
JP2012524524A (en) 2009-04-27 2012-10-18 ノバルティス アーゲー Composition of therapeutic antibodies specific for IL-12 receptor β1 subunit and methods of use
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
US8597650B2 (en) 2009-04-08 2013-12-03 Olle Hernell Methods for treating rheumatoid arthritis with anti-bile salt-stimulated lipase (BSSL) antibodies
WO2010119691A1 (en) 2009-04-16 2010-10-21 国立大学法人東京大学 Diagnosis and treatment of cancer using anti-tmprss11e antibody
DK2419447T3 (en) 2009-04-17 2017-09-25 Immunas Pharma Inc Antibodies that specifically bind to a beta oligomer and use thereof
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
WO2010125003A1 (en) 2009-04-27 2010-11-04 Novartis Ag Compositions and methods for increasing muscle growth
WO2010126137A1 (en) 2009-05-01 2010-11-04 国立大学法人 東京大学 Anti-cadherin antibody
RU2549679C2 (en) 2009-05-04 2015-04-27 Эбботт Рисерч Б.В. Anti-nerve growth factor (ngf) antibodies possessing high stability in vivo
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
JP5808052B2 (en) 2009-05-29 2015-11-10 中外製薬株式会社 Pharmaceutical composition comprising antagonist of EGF family ligand as ingredient
WO2010151632A1 (en) 2009-06-25 2010-12-29 Bristol-Myers Squibb Company Protein purifacation by caprylic acid (octanoic acid ) precipitation
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
ES2614949T3 (en) 2009-08-06 2017-06-02 Immunas Pharma, Inc. Antibodies that specifically bind to beta A oligomers and use thereof
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2468771A4 (en) 2009-08-17 2013-06-05 Forerunner Pharma Res Co Ltd Pharmaceutical composition containing anti-hb-egf antibody as active ingredient
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
EP2480561B1 (en) 2009-09-23 2016-07-13 E. R. Squibb & Sons, L.L.C. Cation exchange chromatography
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
WO2011057188A1 (en) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
EP2499494B1 (en) 2009-11-09 2017-03-08 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
MX357972B (en) 2009-11-13 2018-08-01 Amgen Inc Material and methods for treating or preventing her-3 associated diseases.
WO2011060272A2 (en) 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
NO2501822T3 (en) 2009-11-17 2018-01-13
LT3279215T (en) 2009-11-24 2020-04-10 Medimmune Limited Targeted binding agents against b7-h1
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
KR20130005264A (en) 2010-01-11 2013-01-15 알렉시온 파마슈티칼스, 인코포레이티드 Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
AR080428A1 (en) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulations Stabilized liquid contentivas antibody
EP3342786A1 (en) 2010-01-29 2018-07-04 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
WO2013184761A1 (en) * 2012-06-05 2013-12-12 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
NZ619512A (en) 2010-02-08 2014-10-31 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
PL2535358T3 (en) 2010-02-10 2018-05-30 Fujifilm Ri Pharma Co., Ltd. Radioactive metal-labeled anti-cadherin antibody
WO2011105573A1 (en) 2010-02-26 2011-09-01 株式会社未来創薬研究所 Anti-icam3 antibody and use thereof
WO2011108714A1 (en) 2010-03-04 2011-09-09 中外製薬株式会社 Antibody constant region variant
MX340295B (en) 2010-03-10 2016-07-05 Genmab As Monoclonal antibodies against c-met.
KR20130031247A (en) 2010-03-17 2013-03-28 애보트 리서치 비.브이. Anti-nerve growth factor(ngf) antibody compositions
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
AU2011234988B2 (en) 2010-03-31 2014-10-30 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
ES2608475T3 (en) 2010-04-13 2017-04-11 Celldex Therapeutics, Inc. Antibodies that bind to human CD27 and uses thereof
JP6320753B2 (en) 2010-05-27 2018-05-09 ゲンマブ エー/エス Monoclonal antibody against HER2
SG184427A1 (en) 2010-04-20 2012-11-29 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
CA2797856C (en) 2010-04-30 2018-09-18 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
CN103189073B (en) 2010-05-04 2015-08-12 梅里麦克制药股份有限公司 Antibody of anti-epidermal growth factor receptor (EGFR) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
NZ603829A (en) 2010-05-06 2015-03-27 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
KR20130066631A (en) 2010-05-06 2013-06-20 노파르티스 아게 Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011147982A2 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2 epitope
EP2578231A4 (en) 2010-05-28 2013-10-30 Chugai Pharmaceutical Co Ltd Antitumor t cell response enhancer
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JP6055404B2 (en) 2010-06-15 2016-12-27 ゲンマブ エー/エス Human antibody drug conjugates against tissue factor
EP2585476A4 (en) 2010-06-22 2014-01-22 Neogenix Oncology Inc Colon and pancreas cancer specific antigens and antibodies
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
EP2622091B1 (en) 2010-09-23 2019-03-13 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
US9485812B2 (en) 2010-07-08 2016-11-01 Honda Motor Co., Ltd. High frequency heating coil
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
EP2601220A2 (en) 2010-08-06 2013-06-12 U3 Pharma GmbH Use of her3 binding agents in prostate treatment
LT2606070T (en) 2010-08-20 2017-04-10 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TWI621625B (en) 2010-09-17 2018-04-21 巴克斯歐塔公司 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
JP5843170B2 (en) 2010-09-30 2016-01-13 国立研究開発法人理化学研究所 Method for treating glioma, method for examining glioma, method for delivering desired substance to glioma, and drug used in these methods
JP2013543384A (en) 2010-10-05 2013-12-05 ノバルティス アーゲー Anti-IL12Rbeta1 antibody and its use in the treatment of autoimmune and inflammatory diseases
AU2011323784A1 (en) 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
EP3404043A1 (en) 2010-10-29 2018-11-21 Perseus Proteomics Inc. Anti-cdh3 antibody having high internalization capacity
RU2620071C2 (en) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Multispecific antigen-binding molecule with alternate function to blood coagulation factor viii function
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
KR20130121900A (en) 2010-11-30 2013-11-06 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CN103429737A (en) 2010-11-30 2013-12-04 中外制药株式会社 Cytotoxicity-inducing therapeutic agent
SG10201609301QA (en) 2011-11-30 2016-12-29 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
US9085772B2 (en) 2010-12-27 2015-07-21 National University Corporation Nagoya University Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell
US9315566B2 (en) 2011-01-24 2016-04-19 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
BR112014020821A2 (en) 2012-02-24 2017-07-04 Chugai Pharmaceutical Co Ltd antigen binding molecule for promoting antigen disappearance through fcyriib
CA2850194A1 (en) 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens
BR112013021526A2 (en) 2011-02-25 2016-11-01 Chugai Pharmaceutical Co Ltd fcyriib specific fc antibody
KR101969526B1 (en) 2011-02-28 2019-04-17 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 Medicinal agent for inhibiting metastasis of malignant tumor
US8906635B2 (en) 2011-02-28 2014-12-09 Northshore University Healthsystem Methods of diagnosing Clostridium difficile infection
MX356426B (en) 2011-04-04 2018-05-29 Univ Iowa Res Found Methods of improving vaccine immunogenicity.
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
MX2013011978A (en) 2011-04-15 2015-06-10 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer.
WO2012144208A1 (en) 2011-04-18 2012-10-26 国立大学法人東京大学 Diagnosis and treatment of cancer using anti-itm2a antibody
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TWI609695B (en) 2011-05-10 2018-01-01 安美基公司 Stable formulations and uses thereof for treating or preventing cholesterol related disorders
US9067997B2 (en) 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
RU2719132C2 (en) 2011-06-30 2020-04-17 Чугаи Сейяку Кабусики Кайся Heterodimerised polypeptide
AU2012277376B2 (en) 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
ES2692519T3 (en) 2011-07-01 2018-12-04 Novartis Ag Method to treat metabolic disorders
CN104736174B (en) 2012-07-06 2019-06-14 根马布私人有限公司 Protein dimer with triple mutant
US10323081B2 (en) 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
JP6176849B2 (en) 2011-07-19 2017-08-09 中外製薬株式会社 A stable protein-containing preparation containing arginine amide or a similar compound
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
EP2739652B1 (en) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
RS59728B1 (en) 2011-08-05 2020-02-28 Regeneron Pharma Humanized universal light chain mice
WO2013024517A1 (en) 2011-08-12 2013-02-21 国立感染症研究所 Method for testing for, preventing, and treating infectious disease aspergillus fumigatus; and composition
WO2013027802A1 (en) 2011-08-23 2013-02-28 中外製薬株式会社 Novel anti-ddr1 antibody having anti-tumor activity
WO2013035824A1 (en) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド Cancer stem cell isolation
EP2758535B1 (en) * 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CN104093424A (en) 2011-09-30 2014-10-08 中外制药株式会社 Antigen-binding molecule inducing immune response to target antigen
EP2762564A4 (en) 2011-09-30 2015-04-29 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
EP3617313A1 (en) 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
EP2766033B1 (en) 2011-10-14 2019-11-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
SG10201602904VA (en) 2011-10-17 2016-05-30 Regeneron Pharma Restricted immunoglobulin heavy chain mice
CN110964115A (en) 2011-10-27 2020-04-07 健玛保 Production of heterodimeric proteins
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
BR112014011912A2 (en) 2011-11-16 2017-05-16 Amgen Inc method for treating a mammal that has a tumor
CA2858012A1 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
UY34486A (en) 2011-12-05 2013-07-31 Novartis Ag Antibodies targeting the receptor epidermal growth factor 3 (HER3) directed against domain II of HER3
EP2794656B1 (en) 2011-12-21 2019-02-27 Novartis AG Compositions comprising antibodies targeting factor p and c5
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
MX2014009289A (en) 2012-02-01 2015-09-08 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer.
JP6273212B2 (en) 2012-02-06 2018-01-31 インヒブルクス エルピー CD47 antibody and method of use thereof
WO2013118858A1 (en) 2012-02-09 2013-08-15 中外製薬株式会社 Modified fc region of antibody
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP6280031B2 (en) 2012-03-29 2018-02-14 中外製薬株式会社 Anti-LAMP5 antibody and use thereof
US9764041B2 (en) 2012-04-04 2017-09-19 Perseus Proteomics Inc. Drug conjugate comprising anti-CDH3 (P-cadherin) antibody
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US20140030270A1 (en) 2012-05-03 2014-01-30 Amgen Inc. Methods of treating or preventing cholesterol related disorders
US9416189B2 (en) 2012-05-11 2016-08-16 Microbial Chemistry Research Foundation Anti-CXADR antibody
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013180201A1 (en) 2012-05-30 2013-12-05 中外製薬株式会社 Antigen-binding molecule for eliminating aggregated antigens
CN107964042A (en) 2012-05-30 2018-04-27 中外制药株式会社 Target tissue specific antigen binding molecule
EP3498857A1 (en) 2012-06-11 2019-06-19 Amgen, Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2013187495A1 (en) 2012-06-14 2013-12-19 中外製薬株式会社 ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
EP3552628A1 (en) 2012-09-07 2019-10-16 The Trustees Of Darthmouth College Vista modulators for diagnosis and treatment of cancer
TWI677507B (en) 2012-06-22 2019-11-21 達特茅斯學院基金會 Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
AR091649A1 (en) 2012-07-02 2015-02-18 Squibb Bristol Myers Co Optimization of antibodies that bind to the gene activation lymphocyte 3 (LAG-3) and their uses
EP2876160A4 (en) 2012-07-06 2016-08-10 Kyoto Prefectural Public Univ Corp Differentiation marker for and differentiation control for ocular cells
WO2014021339A1 (en) 2012-07-30 2014-02-06 国立大学法人名古屋大学 Monoclonal antibody against human midkine
EP3597747A1 (en) 2012-08-24 2020-01-22 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
AU2013316441B2 (en) 2012-09-13 2018-08-09 Chugai Seiyaku Kabushiki Kaisha Gene knock-in non-human animal
US20150307945A1 (en) 2012-09-27 2015-10-29 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
EP2902787B1 (en) 2012-09-28 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Method for evaluating blood coagulation reaction
EP2918603B1 (en) 2012-11-08 2018-08-29 University of Miyazaki Antibody capable of specifically recognizing transferrin receptor
CA2886987A1 (en) 2012-11-08 2014-05-15 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
AP201508365A0 (en) 2012-12-05 2015-04-30 Novartis Ag Compositions and methods for antibodies targeting epo
JP2016502850A (en) 2012-12-18 2016-02-01 ノバルティス アーゲー Compositions and methods using peptide tags that bind to hyaluronan
EP2940135A4 (en) 2012-12-27 2016-08-03 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide
WO2014106176A1 (en) 2012-12-28 2014-07-03 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US20150353636A1 (en) 2013-01-10 2015-12-10 Genmab B.V. Human igg1 fc region variants and uses thereof
EP2948477B1 (en) 2013-01-25 2019-10-16 Amgen Research (Munich) GmbH Antibody constructs for cdh19 and cd3
ES2728936T3 (en) 2013-01-25 2019-10-29 Amgen Inc Antibodies directed against CDH19 for melanoma
UY35315A (en) 2013-02-08 2014-09-30 Novartis Ag anti-IL-17A antibodies and their use in the treatment of disorders autoimmune and inflammatory
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP2955226B1 (en) 2013-02-08 2019-06-26 Medical & Biological Laboratories Co., Ltd. Antibodies to human nrg1 protein
CN109769752A (en) 2013-02-20 2019-05-21 瑞泽恩制药公司 The non-human animal of immunoglobulin heavy chain with modification
ES2673583T3 (en) 2013-02-28 2018-06-22 National Cancer Center Insoluble fibrin antibody
US10227396B2 (en) 2013-03-08 2019-03-12 Osaka University Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
CN105246916A (en) 2013-03-14 2016-01-13 诺华股份有限公司 Antibodies against notch 3
SI2970449T1 (en) 2013-03-15 2019-11-29 Amgen Res Munich Gmbh Single chain binding molecules comprising n-terminal abp
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
WO2014174596A1 (en) 2013-04-23 2014-10-30 株式会社医学生物学研究所 Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2912526A1 (en) 2013-05-16 2014-11-20 Kyoto University Method for determining prognosis of cancer
US20160115237A1 (en) 2013-05-24 2016-04-28 The University Of British Columbia Cell senescence markers as diagnostic and therapeutic targets
WO2014200018A1 (en) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag Antibodies receptor 1 ldl similar oxidized lectin and methods of use
AU2014299916A1 (en) 2013-06-24 2015-12-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
WO2014209384A1 (en) 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
AU2014306564B2 (en) 2013-08-14 2019-10-17 Stephane ANGERS Antibodies against frizzled proteins and methods of use thereof
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
CN105722527A (en) 2013-09-04 2016-06-29 国立大学法人大阪大学 DPP-4-targeting vaccine for treating diabetes
US20160229922A1 (en) 2013-09-20 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
JPWO2015068781A1 (en) 2013-11-06 2017-03-09 国立大学法人大阪大学 Antibodies with broad neutralizing activity against group 1 of influenza virus type A
TWI652279B (en) 2013-11-11 2019-03-01 中外製藥股份有限公司 Antigen-binding molecules containing altered antibody variable regions
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JPWO2015083764A1 (en) 2013-12-04 2017-03-16 中外製薬株式会社 Antigen-binding molecules whose antigen-binding ability varies depending on the concentration of the compound and its library
SG10201912793RA (en) 2013-12-24 2020-02-27 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US20160326253A1 (en) 2013-12-27 2016-11-10 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
US10391081B2 (en) 2013-12-27 2019-08-27 Chugai Seiyaku Kabushiki Kaisha FGFR gatekeeper mutant gene and drug targeting same
US20160319013A1 (en) 2013-12-27 2016-11-03 Osaka University Vaccine targeting il-17a
DK3105252T3 (en) 2014-02-12 2019-10-14 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
SG11201607772WA (en) 2014-03-31 2016-10-28 Debiopharm Int Sa Fgfr fusions
EP3126397B1 (en) 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
TW201622746A (en) 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture
DK3151921T3 (en) 2014-06-06 2019-12-02 Squibb Bristol Myers Co Antibodies against glucocorticoid-induced tumor cancer factor receptors (gitr) and applications thereof
TW201625685A (en) 2014-06-18 2016-07-16 梅爾莎納醫療公司 Monoclonal antibodies against HER2 epitope and methods of use thereof
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
WO2016007414A1 (en) 2014-07-08 2016-01-14 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
CN107074948A (en) 2014-07-11 2017-08-18 根马布股份公司 With reference to AXL antibody
JP2018525354A (en) 2015-07-10 2018-09-06 ゲンマブ エー/エス AXL-specific antibody-drug conjugates for cancer treatment
EP3174903A1 (en) 2014-07-31 2017-06-07 Amgen Research (Munich) GmbH Bispecific single chain antibody construct with enhanced tissue distribution
JP2017526350A (en) 2014-07-31 2017-09-14 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Optimized interspecies specific bispecific single chain antibody construct
UY36245A (en) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Antibody constructs to CD3 and cdh19
JP2017527541A (en) 2014-08-01 2017-09-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Anti-CD45RC antibody for use as a drug
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG11201700473QA (en) 2014-08-07 2017-02-27 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
US20170313742A1 (en) 2014-11-03 2017-11-02 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
BR112017008672A2 (en) 2014-11-07 2018-03-20 Eleven Biotherapeutics Inc improved il-6 antibodies
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
JP2018505911A (en) 2014-12-05 2018-03-01 イミュネクスト,インコーポレーテッド Identification of VSIG8 as a putative VISTA receptor and its use to produce a VISTA / VSIG8 modulator
JP2018502598A (en) 2014-12-19 2018-02-01 リジェネサンス ベスローテン フェンノートシャップ Antibodies that bind to human C6 and uses thereof
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag Compositions and methods for antibodies directed to BMP6
SG10201908027QA (en) 2015-03-13 2019-10-30 Squibb Bristol Myers Co Use of alkaline washes during chromatography to remove impurities
WO2016153983A1 (en) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran for protein purification
US20180105554A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran sulfate to enhance protein a affinity chromatography
AU2016250023A1 (en) 2015-04-17 2017-11-02 Amgen Research (Munich) Gmbh Bispecific antibody constructs for CDH3 and CD3
EP3283099A1 (en) 2015-04-17 2018-02-21 H. Hoffnabb-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
AU2016253886B2 (en) 2015-04-28 2019-05-16 Mitsubishi Tanabe Pharma Corporation RGMa binding protein and use thereof
PE9262018A1 (en) 2015-05-29 2018-06-08 Squibb Bristol Myers Co Antibodies member 4 superfamily receptor tumor necrosis factor (OX40) and their uses
TN2017000417A1 (en) 2015-06-05 2019-01-16 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
JP2018530514A (en) 2015-06-24 2018-10-18 ヤンセン ファーマシューティカ エヌブイ Anti-VISTA antibodies and fragments
KR20180021833A (en) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 Antibodies to CD40 with enhanced agonist activity
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
TW201716436A (en) 2015-07-13 2017-05-16 H 朗德貝克公司 Antibodies specific for hyperphosphorylated tau and methods of use thereof
TW201708256A (en) 2015-07-31 2017-03-01 安美基研究(慕尼黑)公司 Antibody constructs for MSLN and CD3
TW201708261A (en) 2015-07-31 2017-03-01 Amgen Res (Munich) Gmbh Antibody constructs for DLL3 and CD3
TW201706307A (en) 2015-07-31 2017-02-16 安美基研究(慕尼黑)公司 Antibody constructs for CD70 and CD3
TW201716441A (en) 2015-07-31 2017-05-16 安美基研究(慕尼黑)公司 Antibody constructs for EGFRVIII and CD3
TW201708257A (en) 2015-07-31 2017-03-01 安美基研究(慕尼黑)公司 Antibody constructs for FLT3 and CD3
WO2017021893A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
EA201890655A1 (en) 2015-09-09 2018-08-31 Новартис Аг Molecules associated with thymusic stromal lymphopoethin (tslp) and methods of application of such molecules
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
BR112018010172A2 (en) 2015-11-19 2018-11-21 Squibb Bristol Myers Co antibodies to glucocorticoid-induced tumor necrosis factor receptor (gitr) and their uses
JP2019503706A (en) 2015-11-30 2019-02-14 ブリストル−マイヤーズ スクウィブ カンパニー Anti-human IP-10 antibodies and their use
TW201731872A (en) 2015-12-18 2017-09-16 諾華公司 Antibodies targeting CD32b and methods of use thereof
WO2017110980A1 (en) 2015-12-25 2017-06-29 中外製薬株式会社 Antibody having enhanced activity, and method for modifying same
EP3405492A1 (en) 2016-01-21 2018-11-28 Novartis AG Multispecific molecules targeting cll-1
AU2017216230A1 (en) 2016-02-03 2018-07-19 Amgen Inc. BCMA and CD3 bispecific T cell engaging antibody constructs
CA3014013A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
EP3423489A1 (en) 2016-03-04 2019-01-09 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
US20200048361A1 (en) 2016-03-14 2020-02-13 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
BR112018068461A2 (en) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugate, pharmaceutical composition, methods for preparing a conjugate and for alleviating a symptom of a cancer.
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CN109071665A (en) 2016-04-18 2018-12-21 塞德斯医疗公司 In conjunction with the agonistic antibody and application thereof of people CD40
MX2018012717A (en) 2016-04-19 2019-05-15 Amgen Res Munich Gmbh Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia.
EA201892440A1 (en) 2016-05-09 2019-04-30 Бристол-Майерс Сквибб Компани Antibodies to tl1a and their applications
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
CA3027561A1 (en) 2016-07-12 2018-01-18 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP2019533981A (en) 2016-07-14 2019-11-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Antibodies against TIM3 and uses thereof
JP2019528312A (en) 2016-08-07 2019-10-10 ノバルティス アーゲー mRNA-mediated immunization methods
JP2019530646A (en) 2016-08-12 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Protein purification method
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
TW201825674A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing bispecific engager molecules
CR20190193A (en) 2016-10-13 2019-08-21 Massachusetts Inst Technology Antibodies that bind zika virus envelope protein and uses thereof
CN109996809A (en) 2016-11-14 2019-07-09 诺华股份有限公司 Composition relevant to fusogenic protein MINION, method and therapeutical uses
EP3541836A1 (en) 2016-11-15 2019-09-25 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
KR20190087525A (en) 2016-11-28 2019-07-24 추가이 세이야쿠 가부시키가이샤 A ligand binding molecule capable of modulating ligand binding activity
CN110072888A (en) 2016-12-16 2019-07-30 H.隆德贝克有限公司 Medicament, purposes and method
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US20200109208A1 (en) 2016-12-23 2020-04-09 Bristol-Myers Squibb Company Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties
JP2020506954A (en) 2017-01-04 2020-03-05 ハー・ルンドベック・アクチエゼルスカベット Antibodies specific for hyperphosphorylated tau for the treatment of eye diseases
TW201833140A (en) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 Anti-fgfr antibodies and methods of use
JP2020506924A (en) 2017-02-02 2020-03-05 アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング Low pH pharmaceutical compositions containing T cell engage antibody constructs
MX2019009498A (en) 2017-02-08 2019-10-02 Novartis Ag Fgf21 mimetic antibodies and uses thereof.
CN110506057A (en) 2017-02-17 2019-11-26 百时美施贵宝公司 ALPHA synapse nucleoprotein antibody and its application
EP3604340A1 (en) 2017-03-24 2020-02-05 Zenyaku Kogyo Co., Ltd ANTI-IgM/B CELL SURFACE ANTIGEN BISPECIFIC ANTIBODY
EP3600415A1 (en) 2017-03-24 2020-02-05 Novartis AG Methods for preventing and treating heart disease
TW201836636A (en) 2017-03-31 2018-10-16 公立大學法人奈良縣立醫科大學 Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
TW201843173A (en) 2017-04-07 2018-12-16 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
US20200109390A1 (en) 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
CA3060856A1 (en) 2017-05-05 2018-11-08 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CA3063659A1 (en) 2017-06-28 2019-01-03 Novartis Ag Methods for preventing and treating urinary incontinence
US20190023788A1 (en) 2017-07-20 2019-01-24 H. Lundbeck A/S Agents, uses and methods for treatment
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
TW201938586A (en) 2017-12-11 2019-10-01 美商安進公司 Continuous manufacturing process for bispecific antibody products
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc Construction of bispecific antibody directed to CD3 and MUC17
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019191416A1 (en) 2018-03-29 2019-10-03 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag Entpd2 antibodies, combination therapies and methods of using the antibodies and combination therapies
WO2020025532A1 (en) 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
US20200055932A1 (en) 2018-08-03 2020-02-20 Amgen Research (Munich) Gmbh Antibody Constructs for CLDN18.2 and CD3
WO2020043670A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
WO2020061210A1 (en) 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2020077212A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020079580A1 (en) 2018-10-15 2020-04-23 Novartis Ag Trem2 stabilizing antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) * 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
AT139258T (en) * 1990-01-12 1996-06-15 Cell Genesys Inc Generation of xenogenic antibodies
EP0746609A4 (en) * 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (en) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies

Also Published As

Publication number Publication date
JP5550026B2 (en) 2014-07-16
EP0754225A4 (en) 2001-01-31
JPH08509612A (en) 1996-10-15
JP2007054076A (en) 2007-03-08
CA2161351C (en) 2010-12-21
CA2161351A1 (en) 1994-11-10
JP5099405B2 (en) 2012-12-19
EP0754225A1 (en) 1997-01-22
JP2012143252A (en) 2012-08-02
WO1994025585A1 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
AU684419B2 (en) Detachable embolic coil assembly
AU675342B2 (en) Electromagnetic transducer
AU667583B2 (en) Detachable embolic coil assembly
DE69429095D1 (en) Humanized antibodies
AU654134B2 (en) Multivalent antigen-binding proteins
US4953313B1 (en) Ear tag for animals
AU687346C (en) A combination of anti-erbB-2 monoclonal antibodies and method of using
AU566943B2 (en) Pest control sachet
EP0426641A3 (en) Promoter for transgenic plants
AU7548196A (en) Improved humanized immunoglobulins
ZA9506215B (en) Antibodies which activate an erythropoletin response
AU2665492A (en) Detachable pusher-vasoocclusive coil assembly with interlocking coupling
AU3811495A (en) Antibodies
AU2872992A (en) Stabilised antibodies
DE68926508D1 (en) Generation of antibodies from transgenic animals
AT412012T (en) Preparation of antibodies by cre-mediated local recombination
AU2118595A (en) Recombinant humanized anti-lk26 antibodies
DE69834527D1 (en) Method of sexing mammalian offspring
SG48760A1 (en) Generation of xenogenetic antibodies
AU4042789A (en) New secretory leader sequences
EP0706320A1 (en) Method of controlling insects
AU696235C (en) Anti-GP39 antibodies and uses therefor
HU9502026D0 (en) A novel family of anti-carcinoembryonic antigen chimeric antibodies
AU4289496A (en) Method of promoting an immune response with a bispecific antibody
DE69310930T2 (en) Improved method for producing barred dispersing agents with reduced sediment case